Prevention of nodules and enhancement of antibody response to genetically engineered recombinant vaccine against Human Chorionic Gonadotropin (hCG) for contraception
Priyanka Tiwari,Mala Srivastava,Rohini Sehgal,Sunesh Kumar,Angamuthu Selvapandiyan,Anupma Kumari,Jagdish C. Gupta,Gursaran Parshad Talwar
DOI: https://doi.org/10.1080/13625187.2024.2359127
2024-06-22
The European Journal of Contraception & Reproductive Health Care
Abstract:Objective: Human Chorionic Gonadotropin (hCG) plays a crucial role in embryo implantation and in maintenance of pregnancy. An immuno-contraceptive approach involves the use of a recombinant hCGβ-LTB vaccine formulated with adjuvant Mycobacterium indicus pranii (MIP), to prevent pregnancy without disturbing ovulation, hormonal profiles, and menstrual cycles in women. The present work in mice was designed to address issues encountered in clinical trials conducted with hCGβ-LTB vaccine, with focus on two primary concerns. Firstly, it aimed to determine the optimal vaccine dosage required to induce a high level of anti-hCG antibodies. Secondly, it aimed to assess the safety profile of the vaccine, specifically injection site reactions in the form of nodules, observed in some of the subjects.
public, environmental & occupational health,obstetrics & gynecology